PRI's Focus on Health Care
View this email in your browser ([link removed])
[link removed]
Divided Congress Doesn't Have to Mean Gridlock Over Healthcare
Newsmax | Sally Pipes
November 22, 2022
As a result of the recent midterm elections, and as of this writing, it looks like the 118th Congress, which will be seated Jan. 3, 2023 will be split, with Democrats set to retain a slim majority in the Senate and Republicans taking control of the House by just a narrow margin of seats.
But divided government doesn’t necessarily mean legislative gridlock.
Read more. . . ([link removed])
What is the Value of the Interchangeability Designation for a Biosimilar?
American Journal of Managed Care | Wayne Winegarden, Robert Popovian & Peter Pitts
November 13, 2022
Biosimilars, to date, have achieved ([link removed]) the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we embark on the primary target: the launch of Humira (adalimumab) biosimilars ([link removed]) . Humira is by far the all-time biopharmaceutical revenue generator, with more than $15 billion ([link removed]) in US sales in 2021.
Read more. . . ([link removed])
A New Plan Brings Clarity To Healthcare Price Transparency - Finally
Forbes | Sally Pipes
November 21, 2022
In health policy, there’s nothing quite as opaque as price transparency. Insurance companies and hospitals tend to say there’s no place for it in the healthcare sector, since medicine is more complicated than cars or groceries.
Other skeptics say that implementing transparency rules is too hard. Hospitals have largely flouted ([link removed]) a two-year-old Trump administration directive that they post their prices online. Parsing the pricing information of those that have complied appears to be beyond the skill set of most ordinary consumers.
Read more . . . ([link removed])
============================================================
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
Copyright © 2022 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.
Our mailing address is:
P.O. Box 60485 | Pasadena, CA 91116
Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.
